Brought to you by 
REGENXBIO completes $70.5mm mezzanine/Series D
02 Jun 2015
Executive Summary
In what the company called a mezzanine round, REGENXBIO Inc. (NAV recombinant AAV vectors for gene drug delivery) raised $70.5mm through an oversubscribed Series D financing. The placement agent was Chardan Capital Markets. To date, the biotech has brought in more than $110mm in venture capital.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
REGENXBIO completes $70.5mm mezzanine/Series D
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice